Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach-Reference-Cited by-同舟云学术

Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach

Published:2020-10-17 Issue:7 Volume:89 Page:1695-1705
ISSN:0031-3998
Container-title:Pediatric Research
language:en
Short-container-title:Pediatr Res

Author:

Depreter Barbara^ORCID,De Moerloose Barbara,Vandepoele Karl,Uyttebroeck Anne,Van Damme An,Terras Eva,Denys Barbara,Dedeken Laurence,Dresse Marie-Françoise,Van der Werff Ten Bosch Jutte,Hofmans Mattias,Philippé Jan,Lammens Tim

Publisher

Springer Science and Business Media LLC

Subject

Pediatrics, Perinatology and Child Health

Link

https://www.nature.com/articles/s41390-020-01199-3.pdf

Reference63 articles.

1. Rasche, M. et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 32, 2167–2177 (2018).

2. De Moerloose, B. et al. Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: results from protocol DB AML-01. Pediatr. Blood Cancer 66, e27605 (2019).

3. Abrahamsson, J. et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J. Clin. Oncol. 29, 310–315 (2011).

4. De Kouchkovsky, I. & Abdul-Hay, M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 6, e441 (2016).

5. Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738–743 (2004).

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute myeloid leukemia stem cell signature gene EMP1 is not an eligible therapeutic target;Pediatric Research;2024-06-15

2. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker;Clinical and Translational Medicine;2024-06

3. Strategies to overcome low MHC-I expression in paediatric and adult tumours;Immunotherapy Advances;2023-12-11

4. Emerging and Future Targeted Therapies for Pediatric Acute Myeloid Leukemia: Targeting the Leukemia Stem Cells;Biomedicines;2023-12-07

5. Dynamic alterations of the transcriptome-wide m6A methylome in cytogenetically normal acute myeloid leukaemia during initial diagnosis and relapse;Genomics;2023-11